Striking a balance between ADC safety and efficacy

“Continued efforts to educate both clinicians and patients, alongside the adoption of proactive safety management protocols, are essential to advancing the safe and effective use of ADCs in cancer treatments.”

On October 9, 2024, Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, spoke to Rakesh Dixit, Cofounder, President and CSO of Regio Biosciences, CEO of Bionavigen, and CSO of Tmab Therapeutics, about the application of ADCs in cancer treatment. This article is based on that interview.

Please enter your email to access content Read now